In This Section
Advertisement
Press Release
-
SNMMI Technologist Section Announces 2017 Award Winners
Jul 20, 2017 — The Society of Nuclear Medicine and Molecular Imaging’s Technologist Section (SNMMI-TS) recognized contributions to and work in the field of nuclear medicine and molecular imaging during the SNMMI 2017 Annual Meeting in Denver, Colorado, held June 10-14. Several awards ceremonies were held to recognize the valuable role that SNMMI-TS members play in advancing the discipline of nuclear medicine technology. -
Radiotherapy Dose Increase to PET/CT-Identified Hypoxic NSCLC Lesions Shows Need for New Approaches
Jul 10, 2017 — Fluorine-18-fluoromisonidazole (FMISO) is a PET radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis. A multicenter French Phase II study featured in the July issue of The Journal of Nuclear Medicine investigated whether a selective radiotherapy dose increase to tumor areas with significant FMISO uptake in NSCLC patients could improve outcomes. -
Novel PET Tracer Detects Small Blood Clots
Jul 6, 2017 — Blood clots in veins and arteries can lead to heart attack, stroke, and pulmonary embolism, which are major causes of mortality. In the featured article of The Journal of Nuclear Medicine’s July 2017 issue, German researchers show that targeting GPIIb/IIIa receptors, the key receptor involved in platelet clumping, with a fluorine-18 labeled ligand is a promising approach for diagnostic imaging. -
The Journal of Nuclear Medicine Impact Factor Increases
Jun 20, 2017 — The Journal of Nuclear Medicine (JNM)—the flagship publication of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)—has again been ranked among the top medical imaging journals worldwide, according to new data released in the 2016 Journal Citation Reports© published by Thomson Reuters. JNM’s impact factor went up from 5.849 (2015) to 6.646 (2016). -
SNMMI’s 64th Annual Meeting Highlights Growing Importance of Theranostics and Showcases New Research
Jun 15, 2017 — More than 5,000 physicians, technologists, scientists and exhibitors gathered for SNMMI’s 2017 Annual Meeting, held June 10-14 in Denver, Colorado. The meeting shined a spotlight on theranostics, featured Germany as the highlight country, showcased exciting new research results, introduced the new Value Initiative, announced the SNMMI Image of the Year, and more! -
Dual-agent PET/MR With Time of Flight Detects More Cancer
Jun 14, 2017 — Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) followed by quantitative scanning significantly improves image quality and detection of bone metastases at a lower dose, according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Prostate PET/CT Targets More Cancer and Improves Patient Care
Jun 14, 2017 — An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific molecular imaging gives these men a fighting chance, especially if their cancer returns, according to research revealed at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
SNMMI Image of the Year: PET and Optical Imaging of Dual-Labeled PSMA Inhibitors Shows Promise for Prostate Cancer Diagnosis and Therapy
Jun 14, 2017 — In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that dual-labeled PSMA-inhibitors based on PSMA-11 enhance preoperative staging, using PET/CT followed by fluorescence-guided surgery. The combined approach results in more accurate detection of PSMA-positive tumor lesions. -
SNMMI Announces Kathleen M. Krisak, BS, CNMT, FSNMMI-TS, as President of Technologist Section During 2017 Annual Meeting
Jun 13, 2017 — Kathleen M. Krisak, BS, CNMT, FSNMMI-TS, a nuclear medicine technologist at the Holyoke Medical Center, Holyoke, Mass., has been elected as the 2017-18 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2017 Annual Meeting, June 10-14 in Denver, Colorado. -
SNMMI Announces Norman E. Bolus, MSPH, MPH, CNMT, FSNMMI-TS, as President-Elect of Technologist Section During 2017 Annual Meeting
Jun 13, 2017 — Norman E. Bolus, MSPH, MPH, CNMT, FSNMMI-TS, program director and assistant professor at the University of Alabama at Birmingham School of Health Professions Clinical and Diagnostics Sciences Department for the Master of Science in Nuclear Medicine Technology Program and interim program director of the Master of Science in Health Physics Program in Birmingham, Alabama, has been elected as the 2017-18 president-elect of the Society of SNMMI-TS. -
Immuno-PET Shows Promise for Detecting and Treating Pancreatic Tumors
Jun 13, 2017 — A first-in-human study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates the feasibility and safety of the novel human monoclonal antibody HuMab-5B1 with highly specific targeting for the cancer antigen (CA) 19-9, which is expressed on pancreatic tumors and a variety of other malignancies, including small cell lung cancer and tumors of the gastrointestinal system. It holds the promise of better identifying tumors and directing treatment. -
Single Dual Time-Point PET Scan Identifies Dual Alzheimer’s Biomarkers
Jun 13, 2017 — Identifying Alzheimer's disease before major symptoms arise is critical to preserving brain function and helping patients maintain quality of life. A new study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that a single dual time-point PET scan could identify important biomarkers of Alzheimer’s. -
SNMMI and SNMMI-TS Welcome New Officers for 2017-18
Jun 13, 2017 — At the 2017 SNMMI Annual Meeting in Denver, the SNMMI and SNMMI-TS welcomed new officers for the coming year. -
SNMMI Elects Bennett S. Greenspan, MD, MS, FACNM, FACR, as President During 2017 Annual Meeting
Jun 12, 2017 — Bennett S. Greenspan, MD, MS, FACNM, FACR, professor of radiology at the Medical College of Georgia, Augusta University, in Augusta, GA, has assumed office as 2017-18 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2017 Annual Meeting, June 10-14, in Denver, Colorado. -
Targeted Radionuclide Treatment for Neuroendocrine Tumors Improves Quality of Life
Jun 12, 2017 — Malignant neuroendocrine tumors, commonly called NETs, are easy to miss and associated with discouraging survival rates and poor quality of life. A study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a novel peptide receptor radionuclide therapy (PRRT) is significantly improving patient wellbeing. -
Personalized PRRT Improves Radiation Delivery to Neuroendocrine Tumors
Jun 12, 2017 — Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient dose of peptide-receptor radionuclide therapy (PRRT), according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Combining Radionuclide Therapy with a PARP Inhibitor Slows Neuroendocrine Tumor Growth
Jun 12, 2017 — Patients with neuroendocrine tumors (NETs) may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more sensitive to radiation therapy, say researchers presenting at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
SNMMI Elects Satoshi Minoshima, MD, PhD, as President-Elect During 2017 Annual Meeting
Jun 12, 2017 — Satoshi Minoshima, MD, PhD, professor of radiology and chairman of the Department of Radiology and Imaging Sciences at the University of Utah, Salt Lake City, Utah, has assumed office as 2017-18 president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2017 Annual Meeting, June 10-14 in Denver, Colorado. -
At Annual Meeting, SNMMI Recognizes New Fellows for Distinguished Service
Jun 12, 2017 — The Society of Nuclear Medicine and Molecular Imaging recognized seven new SNMMI Fellows during a Special Plenary Session at the society’s 2017Annual Meeting, held June 10-14 in Denver, Colorado. The SNMMI Fellowship was established last year to recognize distinguished service to the society as well as exceptional achievement in the field of nuclear medicine and molecular imaging. -
SNMMI Elects Vasken Dilsizian, MD, as Vice President–Elect During 2017 Annual Meeting
Jun 12, 2017 — Vasken Dilsizian, MD, professor of radiology and medicine at the University of Maryland School of Medicine and chief of the Division of Nuclear Medicine at the University of Maryland Medical Center in Baltimore, Maryland, has assumed office as 2017-18 vice president–elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2017 Annual Meeting, June 10-14, in Denver, Colorado. -
Targeted Photodynamic Therapy Shown Highly Effective Against Prostate Cancer
Jun 11, 2017 — Researchers presenting a preclinical study at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated the efficacy and optimal dose for targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery. -
Neuro-Receptor PET Could Provide an Early Warning for Alcoholic Relapse
Jun 11, 2017 — A study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) reveals how brain receptors involved in the compulsion to drink, adapt to alcohol-dependency by reducing their bioavailability, but return to their normal availability after a modest period of detoxification. Receptor availability at the outset of sobriety could also serve as a predictor of long-term success. -
PET Imaging of Atherosclerosis Reveals Risk of Plaque Rupture
Jun 11, 2017 — A new study shows that a hybrid molecular imaging system unites three imaging modalities to map the composition of dangerous arterial plaques before they rupture and induce a major cardiac event. The research was presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Joanna S. Fowler, PhD, Receives SNMMI 2017 Georg Charles de Hevesy Nuclear Pioneer Award
Jun 11, 2017 — Joanna S. Fowler, PhD, senior chemist emeritus of the Department of Energy’s Brookhaven National Laboratory in New York; special volunteer at the National Institutes of Health; emeritus professor in the Department of Chemistry, Stony Brook University; and adjunct professor in the Psychiatry Department, Mount Sinai School of Medicine, has been named this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award for her contributions to nuclear medicine. Fowler was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2017 Annual Meeting, June 9-14 in Denver, Colorado. -
Martin G. Pomper, MD, PhD, Receives SNMMI 2017 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jun 11, 2017 — Martin G. Pomper, MD, PhD, director of nuclear medicine and molecular imaging and professor in the Russell H. Morgan Department of Radiology and Radiological Science at The Johns Hopkins University School of Medicine in Baltimore, Maryland, has been named the 2017 recipient of the prestigious Paul C. Aebersold Award. Pomper was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its annual meeting, held June 10-14 in Denver, Colorado. -
New Grants for Traumatic Brain Injury Research Announced by Julian Bailes, MD, at SNMMI Annual Meeting
Jun 11, 2017 — At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, Julian E. Bailes, MD, a recognized leader in the field of neurosurgery and the impact of brain injury on brain function, announced new grant funding programs of up to $25 million for research on traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE). -
Diagnostic Radiation Exposure Safe for Children, Experts State
Jun 7, 2017 — In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure to medical imaging radiation not only doesn’t increase an adult person’s risk of getting cancer, it doesn’t increase a child’s risk. According to the authors, the long-held belief that even low doses of radiation, such as those received in diagnostic imaging, increase cancer risk is based on an inaccurate, 70-year-old hypothesis and leads to unnecessary fear and misdiagnoses. -
National Decision Support Company and the Society of Nuclear Medicine and Molecular Imaging enter agreement for delivery of Appropriate Use Criteria
Jun 6, 2017 — National Decision Support Company and the Society of Nuclear Medicine and Molecular Imaging announced today that they have entered an agreement to make the SNMMI Imaging Appropriate Use Criteria available to referring physicians and other medical providers. -
PET/MR Shows Arterial CO2 as Potent Vasodilator for Cardiac Stress Testing
Jun 5, 2017 — Using PET/MR imaging, a new international study featured in the June issue of The Journal of Nuclear Medicine demonstrates that increases in partial pressure of arterial carbon dioxide (PaCO2) can safely and efficiently widen blood vessels of the heart during stress tests to help determine heart function. -
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery
Jun 1, 2017 — Breast-conserving surgery is the primary treatment for early-stage breast cancer, but more accurate techniques are needed to assess resection margins during surgery to avoid the need for follow-up surgeries. Now, in a first-in-human study, British researchers have provided a possible solution using Cerenkov luminescence imaging (CLI), which combines optical and molecular imaging. The study is covered in the featured article of The Journal of Nuclear Medicine’s June 2017 issue. -
The SNMMI Annual Meeting: Reaching New Heights in the Mile-High City
May 18, 2017 — The Society of Nuclear Medicine and Molecular Imaging’s 2017 Annual Meeting will be held in Denver, Colorado, June 10-14. It will bring together more than 5,000 physicians, technologists, scientists and exhibitors from around the globe to share and learn about cutting-edge research, advance their knowledge through continuing education sessions, and network. -
SPECT/CT Combined with Fluorescence Imaging Detects Micrometastases
May 10, 2017 — Researchers in The Netherlands have demonstrated that combining SPECT/CT and fluorescence imaging could help surgeons differentiate tumor tissue from normal tissue. The research is detailed in the featured basic science article of the May 2017 issue of The Journal of Nuclear Medicine. -
PET/CT Helps Predict Therapy Effectiveness in Pediatric Brain Tumors
May 2, 2017 — In this first ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body PET/CT scans to determine whether bevacizumab (Avastin) treatment of diffuse intrinsic pontine glioma in children is likely to be effective. The study is featured in the May 2017 issue of The Journal of Nuclear Medicine. -
SNMMI Publishes Appropriate Use Criteria for Ventilation/Perfusion Imaging in Pulmonary Embolism
May 1, 2017 — SNMMI has published appropriate use criteria for ventilation/perfusion (V/Q) imaging in pulmonary embolism. This is the second in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria program for advanced diagnostic imaging. -
PET Radiotracer Design for Monitoring Targeted Immunotherapy
Apr 7, 2017 — In an article published in the April issue of “The Journal of Nuclear Medicine,” researchers at Stanford University in California provide a template for assessing new positron emission tomography (PET) radiotracers that can accurately identify molecules in cancer cells that prevent the immune system from attacking the cancer. -
SNMMI Publishes Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer
Apr 6, 2017 — SNMMI has released a new AUC for bone scintigraphy in prostate and breast cancer. This is the first in a series of new AUC developed by SNMMI in its role as a Medicare qualified provider-led entity. Beginning January 1, 2018, all referring physicians or ordering professionals are required to consult appropriate use criteria using a clinical decision support mechanism before ordering any nuclear medicine study. -
Advanced FDG-PET Image Analysis Identifies Cell Mutations in Cancer Patients
Apr 1, 2017 — Researchers have used positron emission tomography (PET) to successfully identify genetic cell mutations that can cause lung cancer. The research, published in the featured article of the April 2017 issue of “The Journal of Nuclear Medicine,” shows that an advanced image analysis technique, radiomics, can non-invasively identify underlying cell mutations in patients with non-small cell lung cancer (NSCLC). -
Fluciclovine PET/CT Improves Radiotherapy Targeting for Recurrent Prostate Cancer
Mar 6, 2017 — The featured clinical investigation article of the March 2017 issue of "The Journal of Nuclear Medicine" demonstrates that the PET radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualized, targeted therapy. -
New PET Radiotracer Identifies Inflammation in Life-Threatening Atherosclerosis
Mar 1, 2017 — In the featured article of the March 2017 issue of "The Journal of Nuclear Medicine," researchers demonstrate that a new positron emission tomography (PET) radiotracer, gallium-68 (Ga-68)-pentixafor, can quickly and non-invasively identify life-threatening atherosclerotic plaques. The tracer binds to the CXCR4 receptor on inflammatory cells present in atherosclerotic plaques—making it possible to find and treat atherosclerosis early. -
Radiotargeted Therapy with SST2 Antagonists Could Combat Multiple Human Cancers
Feb 6, 2017 — A study published in the February issue of "The Journal of Nuclear Medicine" demonstrates the potential of extending peptide receptor radionuclide therapy targeting the somatostatin receptor to other types of malignancies beyond neuroendocrine tumors. -
New Type of PET Imaging Identifies Primary and Metastatic Prostate Cancer
Feb 1, 2017 — In the featured article from the February 2017 issue of "The Journal of Nuclear Medicine," researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent—a PET radiotracer—is both safe and effective. -
Fear of Diagnostic Low-dose Radiation Exposure Is Overstated, Experts Assert
Jan 9, 2017 — In an article published in the January 2017 issue of "The Journal of Nuclear Medicine," researchers assert that exposure to medical radiation does not increase a person’s risk of getting cancer. -
New Therapeutic Agent Proves More Effective Treatment for Advanced Prostate Cancer
Jan 5, 2017 — A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 (Lu-177)-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). The study is published in the January 2017 issue of "The Journal of Nuclear Medicine" and is the featured article. -
Johannes Czernin, MD, Named Editor-in-Chief for "The Journal of Nuclear Medicine"
Jan 3, 2017 — Johannes Czernin, MD, has assumed leadership of "The Journal of Nuclear Medicine" (JNM), the educational flagship publication of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Czernin is a professor of molecular and medical pharmacology and the chief of the Ahmanson Translational Imaging Division at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). -
3D-Printed Kidney Phantoms Aid Nuclear Medicine Dosing Calibration
Dec 5, 2016 — In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images. Optimal dosing for individual patients can be difficult to determine. That’s where 3D-printed organ models of varying size and shape could be of great use. In a study reported in the December issue of "The Journal of Nuclear Medicine," researchers at the University of Würzburg in Germany focused on kidneys to demonstrate that low-cost 3D printing techniques can be used for quantitative SPECT/CT imaging. -
Novel Anti-PSMA Imaging Agent Quickly Identifies Prostate Cancer Lesions
Dec 2, 2016 — New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the December issue of "The Journal of Nuclear Medicine," the Phase 1 dose-escalation study of Zr-89-desferrioxamine-IAB2M (Zr-89-Df-IAB2M), an anti-PSMA minibody, in patients with metastatic prostate cancer shows its effectiveness in targeting both bone and soft tissue lesions. -
ASNC, IAC and SNMMI Call for Field to Focus on Radiation Dose Optimization in Nuclear Cardiology
Nov 17, 2016 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditation Commission (IAC)’s Nuclear/PET accreditation division and the Society of Nuclear Medicine in Molecular Imaging (SNMMI) are mandating optimized radiation doses in conjunction with the nuclear cardiology studies (i.e., myocardial perfusion imaging) performed throughout the United States and beyond. -
PET Imaging Visualizes Hard-to-Diagnose Cardiac Amyloidosis
Nov 1, 2016 — Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal deposits of proteins in the heart), which is notoriously difficult to diagnose, can be visualized noninvasively with positron emission tomography (PET) using the radiotracer fluorine-18 (F-18)-florbetaben. The study is published in the November issue of "The Journal of Nuclear Medicine." -
Optical and PET/CT Probes Detect Early Signs of Atherosclerosis
Oct 20, 2016 — Researchers at Stanford University have demonstrated for the first time the use of a dual optical and PET/CT activity-based probe, which images vascular inflammation, to detect atherosclerotic plaques. The study is published in the October issue of "The Journal of Nuclear Medicine." -
PET Probe Images Breast Cancer’s Ability to Foil Treatment, Provides Therapy Guidance
Sep 19, 2016 — Cancer biologists know that inhibitor-mediated feedback loop changes (increased expression of a cell surface receptor in response to target inhibition) can result in breast cancer treatment failure and the need for additional therapy. A recent study by researchers at Massachusetts General Hospital in Boston and at Memorial Sloan Kettering in New York City shows that imaging of these cell surface receptor changes with PET probes specific to epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 3 (HER3) directly addresses this unmet need in cancer therapy decision-making, while avoiding the need for repeated biopsies. The study is reported in the September issue of "The Journal of Nuclear Medicine." -
NAS Report Finds U.S. Supply of Critical Medical Isotope Vulnerable
Sep 13, 2016 — The National Academies of Sciences, Engineering, and Medicine have released a report on the state of molybdenum-99 (Mo-99) production, its utilization in medicine, and progress toward eliminating the use of highly enriched uranium (HEU) during production. The report says, “The committee judges that there is a substantial (>50 percent) likelihood of severe molybdenum-99/technetium-99m supply shortages after October 2016, lasting at least until current global suppliers complete their planned capacity expansions.” -
Call for the Standardization of Pediatric Nuclear Medicine
Sep 6, 2016 — The Nuclear Medicine Global Initiative, which was formed in 2012 and consists of 13 international organizations, focused on pediatric nuclear medicine for its first project. Its final report, published in the July issue of "The Journal of Nuclear Medicine," sets forth recommendations for achieving global standards for the administration of radiopharmaceuticals in children. -
SNMMI 2016-2018 Wagner-Torizuka Fellowship Recipients Announced
Aug 23, 2016 — SNMMI is pleased to announce the recipients of the 2016-2018 SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by the late Henry N. Wagner, Jr., MD, and the late Kanji Torizuka, MD, PhD, is designed to provide extensive training and experience in the fields of nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. Applications for the 2017-2019 SNMMI Wagner-Torizuka Fellowship are due by January 20, 2017. -
Novel Tracer Safely and Effectively Maps Sentinel Lymph Nodes in Breast Cancer Patients
Aug 17, 2016 — A recent study by researchers at Peking University Cancer Hospital & Institute demonstrates the effectiveness and safety of Tc-99m-rituximab, a new SLN radiotracer, that targets the antigen CD20, which is expressed extensively in lymph nodes. The study is published in the August issue of "The Journal of Nuclear Medicine." -
SNMMI Technologist Section Announces Award Winners
Jul 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging’s Technologist Section (SNMMI-TS) recognized contributions to and work in the field of nuclear medicine and molecular imaging during the SNMMI 2016 Annual Meeting in San Diego, California. Several awards ceremonies were held to recognize the valuable role that SNMMI-TS members play in advancing the discipline of nuclear medicine technology. -
SNMMI Honors Outstanding Contributors at Annual Meeting
Jul 13, 2016 — SNMMI recognized contributions to the field of nuclear medicine and molecular imaging during its 2016 Annual Meeting in San Diego, Calif. Several awards ceremonies were held to recognize the valuable role SNMMI members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions. -
PET/MRI: A One-Stop Imaging Test to Detect Prostate Cancer?
Jul 11, 2016 — A University of Michigan study published in the July issue of "The Journal of Nuclear Medicine" reports that combining PET imaging with multi-parametric MR improves the accuracy of targeted prostate biopsies. -
Journal of Nuclear Medicine Impact Factor Third Highest Worldwide Among Medical Imaging Journals
Jun 30, 2016 — "The Journal of Nuclear Medicine" (JNM)—the flagship publication of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)—has again been ranked among the top medical imaging journals worldwide, according to new data released in the 2015 Journal Citation Reports© published by Thomson Reuters. JNM earned an impact factor of 5.849—ranking third of the 124 journals included in the medical imaging category. -
SNMMI Named a Medicare Qualified Provider-Led Entity in the Appropriate Use Criteria Program for Advanced Diagnostic Imaging
Jun 22, 2016 — SNMMI has been named a qualified provider-led entity under the Medicare Appropriate Use Criteria program for advanced diagnostic imaging. This will allow referring physicians to use SNMMI’s appropriate use criteria to fulfill the requirements of the 2014 Protecting Access to Medicare Act. -
SNMMI’s 63rd Annual Meeting Highlights History of FDG and Showcases New Research
Jun 16, 2016 — More than 5,700 physicians, technologists, scientists and exhibitors gathered at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2016 Annual Meeting, held June 11-15 in San Diego, Calif. -
SNMMI Image of the Year: Novel PET Imaging Demonstrates Relationship Between Tau Buildup and Neurodegeneration in Alzheimer’s Patients
Jun 15, 2016 — Positron emission tomography (PET) with three different radiotracers can now measure amyloid plaques, tau tangles and metabolic activity in the brains of living Alzheimer’s patients. This multimodal study shows significant correlation between increased tau and decreased metabolic activity in the brain—a clear sign of neurodegeneration—reveal researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
PET/CT Imaging of Prostate Cancer Proves Accurate Biopsy Guide
Jun 15, 2016 — Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of defense, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and pre-operative planning to root out the full extent of disease, researchers revealed at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
CT-Based Calculations Improve Accuracy of PET for Cancer Patients
Jun 14, 2016 — Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring LBM takes changes in individual body composition into account for better staging of disease and therapy monitoring, say researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Novel Portable Diagnostic Tool Pairs Optical and Gamma Imaging
Jun 14, 2016 — Bigger isn’t always better, especially when it comes to a new and surprisingly portable molecular imaging system that combines optical imaging at the surface level and scintigraphy, which captures the physiological function of what lies beneath, announced developers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
SNMMI Announces Kathleen M. Krisak, BS, CNMT, FSNMMI-TS, as President-Elect of Technologist Section During 2016 Annual Meeting
Jun 13, 2016 — Kathleen M. Krisak, BS, CNMT, FSNMMI-TS, a nuclear medicine technologist at the Holyoke Medical Center, Holyoke, Mass., has been elected as the 2016-17 president-elect of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2016 Annual Meeting, June 11-15 in San Diego, Calif. -
H. William Strauss, MD, Receives 2016 Benedict Cassen Prize for Research in Cardiovascular Nuclear Medicine
Jun 13, 2016 — H. William (Bill) Strauss, MD, FACNM, a pioneer in the field of cardiovascular nuclear medicine, was awarded the Benedict Cassen Prize, often considered the Nobel Prize of nuclear medicine, during the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in San Diego, Calif. This honor is given every two years by the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) to a living scientist or physician-scientist whose work has led to a major advance in basic or clinical nuclear medicine science. -
SNMMI Announces Sara G. Johnson, MBA, CNMT, NCT, FSNMMI-TS, as President of Technologist Section During 2016 Annual Meeting
Jun 13, 2016 — Sara G. Johnson, MBA, CNMT, NCT, FSNMMI-TS, chief technologist/administrative officer and research coordinator for nuclear medicine with the VA San Diego Healthcare System in San Diego, Calif., has been elected as the 2016-17 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2016 Annual Meeting, June 11-15 in San Diego, Calif. -
SNMMI Elects Bennett S. Greenspan, MD, MS, FACNM, FACR, as President-Elect During 2016 Annual Meeting
Jun 13, 2016 — Bennett S. Greenspan, MD, MS, FACNM, FACR, professor of radiology at the Medical College of Georgia, Augusta University, in Augusta, GA, has assumed office as 2016-17 President-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2016 Annual Meeting, June 11-15, in San Diego, Calif. -
SNMMI Elects Satoshi Minoshima, MD, PhD, as Vice President-Elect During 2016 Annual Meeting
Jun 13, 2016 — Satoshi Minoshima, MD, PhD, professor of radiology and chairman of the Department of Radiology and Imaging Sciences at the University of Utah, Salt Lake City, Utah, has assumed office as 2016-17 vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2016 Annual Meeting, June 11-15, in San Diego, Calif. -
SNMMI and SNMMI-TS Welcome New Officers for 2016-17
Jun 13, 2016 — At the 2016 SNMMI Annual Meeting, the SNMMI and SNMMI-TS welcomed new officers for the coming year. -
SNMMI Creates Fellowship to Recognize Distinguished Service
Jun 13, 2016 — The Society of Nuclear Medicine and Molecular Imaging announced the creation of an SNMMI Fellowship recognizing distinguished service to SNMMI as well as exceptional achievement in the field of nuclear medicine and molecular imaging. The announcement was made during today’s Special Plenary Session at the society’s 2016 Annual Meeting, held June 11-15 in San Diego, Calif. -
FDG PET Evaluates Immunotherapy for Non-Small Cell Lung Cancer
Jun 13, 2016 — Non-small cell lung cancers (NSCLC) have a collective reputation for not responding very well to chemotherapy. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are presenting a means of evaluating an immunotherapy that fights off NSCLC by strengthening a patient’s own immune system. -
Molecular Imaging of Neuroendocrine Tumors Optimizes Radiotherapy Dose
Jun 13, 2016 — Aggressive neuroendocrine cancer is something of a dark horse—a rare, elusive and persevering force linked to discouraging long-term survival rates. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are presenting a molecular imaging technique that allows oncologists to set patients’ radiotherapy doses right at that critical limit of delivering the most powerful kill to neuroendocrine tumors (NETs) while protecting vulnerable vital organs. -
PET Points to Tau Protein as Leading Culprit in Alzheimer’s
Jun 13, 2016 — Alzheimer’s is a devastating and incurable disease marked by beta-amyloid and tau protein aggregations in the brain, yet the direct relationship between these proteins and neurodegeneration has remained a mystery. New molecular imaging research is revealing how tau, rather than amyloid-deposition, may be more directly instigating neuronal dysfunction, say presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
SNMMI Elects Sally W. Schwarz, MS, RPh, BCNP, as President During 2016 Annual Meeting
Jun 13, 2016 — Sally W. Schwarz, MS, RPh, BCNP, professor of radiology at Washington University School of Medicine in St. Louis, Mo., has assumed office as 2016-17 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2016 Annual Meeting, June 11-15, in San Diego, Calif. -
Pretargeted Radioimmunotherapy May Eliminate Colorectal Cancer
Jun 12, 2016 — An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models. -
PET/CT Reveals Adaptations of the Alcoholic Brain
Jun 12, 2016 — Alcoholism is a devastating disorder that too often leads to a perpetual cycle of abuse. An emerging molecular imaging technique may provide a way to break that cycle. It could signal patients’ heightened risk and lead to targeted drug treatments that reduce the compulsion to drink, say researchers presenting at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Blood Test Predicts Success of Neuroendocrine Cancer Therapy
Jun 12, 2016 — Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy (PRRT) before they commit to a course of treatment. -
Markle Foundation Partners with SNMMI to Commemorate 75th Anniversary of Transformative Treatment for Thyroid Disease
Jun 12, 2016 — This year marks the 75th anniversary of the first treatment of thyroid disease with radioactive iodine. In January 1941, Dr. Saul Hertz administered a cyclotron-produced mixture of iodine-130 and iodine-131 to a patient at Massachusetts General Hospital for the treatment of Graves’ disease. Purchase of that cyclotron was funded by the Markle Foundation, which has now partnered with SNMMI to commemorate this anniversary at SNMMI’s Annual Meeting, June 11-15 in San Diego, Calif. -
PET Detects Neuroinflammation in Multiple Sclerosis
Jun 12, 2016 — The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular imaging is bringing researchers closer to identifying them, while providing a means of evaluating next-generation therapies for MS, say researchers introducing a study at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Ross McDougall, MB, ChB, PhD, Receives SNMMI 2016 Georg Charles de Hevesy Nuclear Pioneer Award
Jun 12, 2016 — Ross McDougall, MB, ChB, PhD, professor emeritus of radiology and medicine at Stanford University, Stanford, Calif., has been named this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine. McDougall was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) at its 2016 Annual Meeting, held June 11-15 in San Diego, Calif. -
Peter S. Conti, MD, PhD, Receives SNMMI 2016 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jun 12, 2016 — Peter S. Conti, MD, PhD, FACNP, FACR, professor of radiology, pharmaceutical sciences and biomedical engineering, and director of the Molecular Imaging Center, Keck School of Medicine, University of Southern California, Los Angeles, has been named the 2016 recipient of the prestigious Paul C. Aebersold Award. Conti was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its annual meeting, held June 11-15 in San Diego, Calif. -
Predicting Advanced Prostate Cancer Outcomes with NaF-PET/CT
Jun 7, 2016 — A recent pilot study reported in the June issue of "The Journal of Nuclear Medicine" found that NaF-PET/CT accurately detects bone metastases in patients with advanced prostate cancer, and follow-up scans over time correlate clearly with clinical outcomes and patient survival. -
A Better Way to Diagnose and Manage Neuroendocrine Tumors
May 9, 2016 — A recent study reported in the May issue of "The Journal of Nuclear Medicine" demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors (NETS), and could significantly impact treatment management. -
SPECT-MRI Fusion Minimizes Surgery for Diagnosis of Early-stage Cervical Cancer Patients
Apr 14, 2016 — A recent study reported in the April issue of "The Journal of Nuclear Medicine" found that cervical cancer patients without enlarged lymph nodes could benefit from SPECT-MRI imaging of their sentinel lymph nodes (SLNs) to assess whether metastases are present. -
Twin Study: Genetics and Environment Affect Different Regions of the Brain
Mar 1, 2016 — A recent study, reported in the March issue of "The Journal of Nuclear Medicine," found evidence that genetic influence on cerebral glucose metabolism played a major role in the bilateral parietal lobes and the left temporal lobe of the human brain, while environmental influences after birth dominated in other regions. -
A Better Way to Image Metastatic Prostate Cancer
Jan 27, 2016 — A recent study, reported in the January issue of "The Journal of Nuclear Medicine," shows in a prospective, systematic manner that a PET/CT scan, using the radiotracer F-18-DCFBC to target prostate-specific membrane antigen (PSMA), is significantly more effective than other detection methods currently in use. -
Combined Imaging Modalities May Change Cancer Management
Dec 10, 2015 — PET/CT and whole-body MRI detect extraskeletal disease that may change the management of high-risk breast and prostate cancer patients, according to a recent study reported in the December issue of The Journal of Nuclear Medicine. -
Molecular Imaging Study Reveals Improved Detection of Early Recurrent Prostate Cancer
Sep 17, 2015 — A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine. -
SNMMI 2015-2017 Wagner-Torizuka Fellowship Recipients Announced
Sep 1, 2015 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2015-2017 SNMMI Wagner-Torizuka Fellowship. -
PET Imaging Detects Fast-Growing Prostate Cancer
Aug 20, 2015 — A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. -
SNMMI Honors Outstanding Contributors at Annual Meeting
Aug 17, 2015 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization, recognized contributions to the field of nuclear medicine and molecular imaging during its 2015 Annual Meeting in Baltimore, Md. -
SNMMI Technologist Section Announces Award Winners
Aug 17, 2015 — The Society of Nuclear Medicine and Molecular Imaging’s Technologist Section (SNMMI-TS)—an international scientific and medical organization—recognized contributions to and work in the field of nuclear medicine and molecular imaging during its 2015 Annual Meeting in Baltimore, Md. -
Imaging Advances in Diagnosis and Treatment: A Window into the Future
Jun 29, 2015 — More than five thousand physicians, technologists, scientists and exhibitors gathered at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2015 Annual Meeting, held June 6-10 in Baltimore, Md. -
Journal of Nuclear Medicine Impact Factor Increases
Jun 25, 2015 — The Journal of Nuclear Medicine (JNM)—the flagship publication of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)—has again been ranked among the top medical imaging journals worldwide, according to new data released in the 2014 Journal Citation Reports© published by Thomson Reuters. -
Your Response Is Critical.
Jun 24, 2015 — A discussion is taking place that could change the course of the nuclear medicine profession. Your response is critical. If you have not already done so, please carefully review the following information and the two linked documents and respond as soon as possible. -
Novel PET Tracer Narrows In on Life-Threatening Blood Clots
Jun 8, 2015 — Fatal cardiac events are often preceded by abnormal blood clots, also called thrombosis. Scientists have now developed a molecular imaging technique that could save lives by revealing troublesome thrombi, according to a study presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Molecular Imaging Reveals Marker of Neurodegenerative Disease
Jun 8, 2015 — Brain researchers have been working for years on targeting a cellular process involved in neurodegeneration and cognitive dysfunction. A specialized molecular imaging agent does the job by binding to a transporter of the neurotransmitter acetylcholine, a major mediator of the central nervous system, say presenters at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Amyloid Scan of the Heart Predicts Major Cardiac Events
Jun 8, 2015 — Amyloid build-up is commonly talked about in relation to Alzheimer’s disease, but amyloidosis can be found throughout the body. An excessive accumulation of these insoluble proteins could cause a heart attack or even death. A new molecular imaging scan of amyloid in the heart could help diagnose the problem, say researchers at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
PET Detects More Prostate Cancer than Conventional Imaging
Jun 8, 2015 — Research presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a new molecular imaging agent finds prostate cancer that has spread to other tissues by locking in on an enzyme called prostate specific membrane antigen (PSMA), associated with prostate cancer. -
PET/CT Captures Hidden Source of Neuroendocrine Cancer
Jun 8, 2015 — The origin of cancer is often obscured by metastases—tumors that have already spread to other tissues. This is especially the case for neuroendocrine tumors (NETs), a malignancy of nerve cells scattered throughout various organ systems that are sensitive to the signaling of neurotransmitters and hormones. An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Cloud-based Neuroimaging Analysis Could Aid Alzheimer’s Diagnosis
Jun 8, 2015 — Alzheimer’s disease remains a chronic, incurable neurodegenerative disease and a worldwide health concern. Equally as important as developing comprehensive diagnostic tests is finding a means of normalizing all the ensuing data—and that technology has arrived, say researchers at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
SNMMI Elects Sally W. Schwarz, MS, RPh, BCNP, as President-Elect During 2015 Annual Meeting
Jun 8, 2015 — Sally W. Schwarz, MS, RPh, BCNP, professor in radiology at Washington University School of Medicine in St. Louis, Mo., has assumed office as 2015-16 president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2015 Annual Meeting, June 6-10, in Baltimore, Md. -
SNMMI Elects Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, as President During 2015 Annual Meeting
Jun 8, 2015 — Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, tenured associate professor of radiology and of biomedical engineering at the University of Southern California (USC), has been elected as the 2015-16 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2015 Annual Meeting, June 6-10 in Baltimore, Md. -
SNMMI Elects Bennett S. Greenspan, MD, MS, FACNM, FACR, as Vice President-Elect During 2015 Annual Meeting
Jun 8, 2015 — Bennett S. Greenspan, MD, MS, FACNM, FACR, professor of radiology at the Medical College of Georgia, Georgia Regents University, in Augusta, Ga., has assumed office as 2015-16 vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2015 Annual Meeting, June 6-10, in Baltimore, Md. -
SNMMI Announces Sara G. Johnson, MBA, CNMT, NCT, FSNMMI-TS, as President-Elect of Technologist Section During 2015 Annual Meeting
Jun 8, 2015 — Sara G. Johnson, MBA, CNMT, NCT, FSNMMI-TS, research coordinator for nuclear medicine and a staff nuclear medicine technologist with the VA San Diego Healthcare System in San Diego, Calif., has been elected as the 2015-16 president-elect of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2015 Annual Meeting, June 6-10 in Baltimore, Md. -
SNMMI Announces Aaron Scott, MIS, CNMT, NMAA, FSNMMI-TS, as President of Technologist Section During 2015 Annual Meeting
Jun 8, 2015 — Aaron Scott, MIS, CNMT, NMAA, FSNMMI-TS, a nuclear medicine advanced associate at Piedmont Healthcare System in Fayetteville, Ga., has been elected as the 2015-16 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2015 Annual Meeting, June 6-10, in Baltimore, Md. -
Follow-Up PET/CT More Than 95% Sensitive for Non-Hodgkin Lymphoma
Jun 8, 2015 — Non-Hodgkin lymphoma (NHL), a potentially devastating cancer of the blood and immune system, can range from relatively easy to treat to very aggressive. For more aggressive cases, post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment, say researchers presenting during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Theranostic Drug Personalizes Prostate Cancer Imaging and Therapy
Jun 8, 2015 — A novel radionuclide drug tackles the challenge of prostate cancer imaging and takes a turn as a cancer-killing therapy for tumors in and out of the prostate, according to research presented during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
PET Reveals Inflammatory Cycle in the Brain
Jun 8, 2015 — Neuroinflammation caused by a reactive immune system could be tripping off the neurodegeneration seen in certain dementias, multiple sclerosis, and other deadly diseases of the nervous system. A novel molecular imaging technique could be the key to understanding how best to treat these and other devastating diseases, according to a recent study presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
SNMMI Announces the Election of Neil A. Petry, MS, RPh, BCNP, to Board of Directors
Jun 8, 2015 — Neil A. Petry MS, RPh, BCNP, associate professor of radiology and medical physics graduate program faculty member at the Duke University Medical Center in Durham, NC, has been elected director-at-large of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
SNMMI Image of the Year: Theranostic Drug Unites Molecular Imaging and Therapy for Prostate Cancer
Jun 8, 2015 — A novel molecular imaging technology not only detects prostate cancer that has spread throughout the body but also provides a potent and minimally invasive method of therapy, reveal researchers at the 2015 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. -
Amyloid PET May Lead to Better Treatment for Alzheimer’s Patients
Jun 8, 2015 — New research presented during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that amyloid positron emission tomography (amyloid PET) scans of the brain provide clearer diagnosis and earlier, more effective treatment for Alzheimer’s patients, when results of a more conventional PET scan remain ambiguous. -
Dynamic Whole-Body PET Detects More Cancer
Jun 8, 2015 — Imaging lung cancer requires both precision and innovation. With this aim, researchers have developed a technique for clinical positron emission tomography (PET) imaging that creates advanced whole-body parametric maps, which allow quantitative evaluation of tumors and metastases throughout the body, according to research announced at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Theranostic PET Takes on Both Ovarian and Prostate Cancer
Jun 8, 2015 — A first-in-human study revealed at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment. -
Molecular MRI Aims At Component of Multiple Cancers
Jun 8, 2015 — A relatively new biomarker called prostate-specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Hybrid Scanner Combines Five Molecular Imaging Technologies
Jun 8, 2015 — Scientists are taking medical imaging research and drug discovery to a new level by developing a molecular imaging system that combines several advanced technologies for all-in-one imaging of both tissue models and live subjects, say presenters at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). -
Michael E. Phelps, PhD, Receives SNMMI 2015 Georg Charles de Hevesy Nuclear Pioneer Award
Jun 7, 2015 — Michael E. Phelps, PhD, the Norton Simon professor and chair of the University of California, Los Angeles (UCLA), Department of Molecular & Medical Pharmacology, has been named this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine. Phelps was presented the award by SNMMI—an international scientific and medical organization—during its 2015 Annual Meeting, June 6-10 in Baltimore, Md. -
David W. Townsend, PhD, Receives SNMMI 2015 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Jun 7, 2015 — David W. Townsend, PhD, professor in the Department of Diagnostic Imaging at the National University Hospital of Singapore and director of the A*STAR-NUS Clinical Imaging Research Cen-tre in Singapore, has been named this year’s recipient of the prestigious Paul C. Aebersold Award. Townsend was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2015 Annual Meeting, held June 6-10 in Baltimore, Md. -
Nuclear Medicine Scan Has Potential to Identify which Cancer Patients Could Benefit from Aromatase Inhibitor Treatment
May 7, 2015 — A new, noninvasive nuclear medicine test can be used to determine whether aromatase inhibitor treatment will be effective for specific cancer patients, according to a recent study reported in The Journal of Nuclear Medicine. -
Recurrence of Prostate Cancer Detected Earlier with Innovative PSMA-ligand PET/CT
May 4, 2015 — A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy. Discovering a recurrence early can strongly influence further clinical management, so it is especially noteworthy that this hybrid PSMA-ligand identified a large number of positive findings in the clinically important range of low PSA-values (<0.5ng/mL). -
PET/MR Can Effectively Diagnose Cause of Unclear Foot Pain
Mar 9, 2015 — A single scan could diagnose the cause of foot pain better and with less radiation exposure to the patient than other methods, according to a study in the March 2015 issue of The Journal of Nuclear Medicine. -
New Research Shows High Value of Additional PET/CT Scans in Follow-Up of Lung Cancer Patients
Feb 18, 2015 — New research from Johns Hopkins School of Medicine reveals a high value of scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer. -
Novel Radioguided Brain Surgery Technique Could Help Pinpoint Cancerous Tissue
Jan 27, 2015 — A novel radioguided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, with low radiation exposure for both patients and surgeons. -
Nuclear Medicine Treatment Shows Promise for Cancer Therapy
Dec 9, 2014 — Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. -
SNMMI Introduces Infographic Explaining Nuclear Medicine Therapy
Nov 20, 2014 — SNMMI has released a new infographic showing how certain types of cancer can be treated using nuclear medicine therapy. -
Novel Molecular Imaging Drug Offers Better Detection of Prostate Cancer
Nov 11, 2014 — A new study, published in the November issue of The Journal of Nuclear Medicine, demonstrates the potential of a novel molecular imaging agent to detect and visualize early prostate cancer in soft tissue, lymph nodes and bone. -
FDG-PET/CT Shows Promise for Breast Cancer Patients Younger Than 40
Oct 1, 2014 — Researchers at Memorial Sloan Kettering found that PET/CT imaging of patients younger than 40 who were initially diagnosed with stage I–III breast cancer resulted in change of diagnosis. As reported in the October issue of The Journal of Nuclear Medicine, while guidelines recommend FDG-PET/CT imaging only for women with stage III breast cancer, it can also help physicians more accurately diagnose young breast cancer patients initially diagnosed with earlier stages of the disease. -
SNMMI 2014-2016 Wagner-Torizuka Fellowship Recipients Announced
Sep 2, 2014 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2014-2016 SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by the late Henry N. Wagner, Jr., MD, and the late Kanji Torizuka, MD, PhD, is designed to provide extensive training and experience in the fields of nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. -
PET/CT Using FDG-labeled Leucocytes May Be Useful in Detecting Infection in Acute Pancreatitis Patients
Aug 5, 2014 — A new study diagnosing infection in patients with pancreatic fluid collections may swiftly and accurately rule out active infection in the body. As reported in the August issue of The Journal of Nuclear Medicine, this treatment may assist in bringing nuclear medicine to the forefront of clinical management. -
A Few Circulating Cancer Cells Could Cue Risk of Metastases
Jun 9, 2014 — A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients’ chances of survival, say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting. -
Fair and Adequate Reimbursement is Vital to Developing Life-Saving Medical Treatments
Jun 17, 2008 -
SNM Image of the Year: Molecular Imaging, From Head to Toe
Jun 16, 2008 -
New Molecular Imaging Pharmaceuticals Could Help Identify Metastatic Prostate Cancer
Jun 16, 2008 -
PET Scans Reveal Hormone Replacement Therapy May Be Beneficial for Postmenopausal Women
Jun 16, 2008 -
SNM Announces Cybil Nielsen as President-Elect of Technologist Section at 55th Annual Meeting in New Orleans, La.
Jun 15, 2008 -
SNM Names Mark Wallenmeyer as President of Technologist Section During 55th Annual Meeting in New Orleans, La.
Jun 15, 2008 -
SNM Names Dominique Delbeke as Vice-President Elect During 55th Annual Meeting in New Orleans, La.
Jun 15, 2008 -
SNM Names Michael Graham as President-Elect During 55th Annual Meeting in New Orleans, La.
Jun 15, 2008 -
SNM Names Robert Atcher as President During 55th Annual Meeting in New Orleans, La.
Jun 15, 2008 -
SNM's 2008-09 Leaders Take Office During 55th Annual Meeting in New Orleans, La.
Jun 15, 2008 -
Radiation Dosage Based on Body Mass Index Could Be Next Step for Personalized Medicine
Jun 13, 2008 -
Researchers Are a Quick Study When Assessing Drugs for Alzheimer’s Disease
Jun 13, 2008 -
Every Patient Is Unique: Individualized Therapies for Non-Hodgkin’s Lymphoma
Jun 13, 2008 -
PET/CT Scan Could Be Valuable Noninvasive Tool for Determining Stages of Ovarian Cancer
Jun 13, 2008 -
New Study Shows Potential to Treat or Prevent Viral Cancers
Jun 13, 2008 -
Personalizing Medicine: New Research Shows Potential of Targeted Therapies for Cancer
Jun 13, 2008 -
New Therapy Shows Promise for Fighting Treatment-Resistant Cancer Cells
Jun 12, 2008 -
New Molecular Imaging Techniques May Lead to Advances in Disease Treatment
Jun 12, 2008 -
PET Imaging Focuses on Medication's Purported Ability to Improve Mental Performance
Jun 12, 2008 -
Molecular Imaging Sheds New Light on Progression of Alzheimer's Disease
Jun 12, 2008 -
First Semiconductor-Based PET Scanner Demonstrates Strong Potential to Aid in Early Diagnosis of Disease
Jun 12, 2008 -
New Possibilities for Breast Cancer Treatment on the Horizon
Jun 12, 2008 -
New Test Could Aid Children Suffering from Reflux Disease
Jun 12, 2008 -
PET Imaging Detects Early, "Silent Heart" Stage of Disease in Asymptomatic Diabetic Patients
Jun 12, 2008